{"name":"Laboratorios Sophia S.A de C.V.","slug":"laboratorios-sophia-s-a-de-c-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Artelac","genericName":"Artelac","slug":"artelac","indication":"Other","status":"phase_1"},{"name":"Sodium hyaluronate 0.4%","genericName":"Sodium hyaluronate 0.4%","slug":"sodium-hyaluronate-0-4","indication":"Other","status":"marketed"},{"name":"Corneregel","genericName":"Corneregel","slug":"corneregel","indication":"Other","status":"phase_1"},{"name":"Krytantek","genericName":"Krytantek","slug":"krytantek","indication":"Other","status":"discontinued"},{"name":"Manzanilla Sophia®","genericName":"Manzanilla Sophia®","slug":"manzanilla-sophia","indication":"Other","status":"marketed"},{"name":"PRO-087","genericName":"PRO-087","slug":"pro-087","indication":"Other","status":"marketed"},{"name":"PRO-155","genericName":"PRO-155","slug":"pro-155","indication":"Other","status":"marketed"},{"name":"PRO-167","genericName":"PRO-167","slug":"pro-167","indication":"Other","status":"phase_1"},{"name":"Prednefrin","genericName":"Prednefrin","slug":"prednefrin","indication":"Other","status":"phase_3"},{"name":"Zymar®","genericName":"Zymar®","slug":"zymar","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"PRO-148","genericName":"PRO-148","slug":"pro-148","indication":"Dry eye disease","status":"phase_3"},{"name":"Alleance®","genericName":"Alleance®","slug":"alleance","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"Meticel Ofteno®","genericName":"Meticel Ofteno®","slug":"meticel-ofteno","indication":"Dry eye syndrome","status":"marketed"},{"name":"Krytantek Ofteno®","genericName":"Krytantek Ofteno®","slug":"krytantek-ofteno","indication":"Glaucoma (intraocular pressure reduction)","status":"phase_3"},{"name":"Meticel Ofteno® 0.5%","genericName":"Meticel Ofteno® 0.5%","slug":"meticel-ofteno-0-5","indication":"Dry eye syndrome / Keratoconjunctivitis sicca","status":"marketed"},{"name":"Optive®","genericName":"Optive®","slug":"optive","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"marketed"},{"name":"Sodium Hyaluronate Ophthalmic 0.4%","genericName":"Sodium Hyaluronate Ophthalmic 0.4%","slug":"sodium-hyaluronate-ophthalmic-0-4","indication":"Dry eye syndrome / Keratoconjunctivitis sicca","status":"marketed"},{"name":"Sodium hyaluronate 0.15%","genericName":"Sodium hyaluronate 0.15%","slug":"sodium-hyaluronate-0-15","indication":"Dry eye syndrome","status":"marketed"},{"name":"Systane Ultra Preservative Free","genericName":"Systane Ultra Preservative Free","slug":"systane-ultra-preservative-free","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Dorzolamide-timolol and latanoprost","genericName":"Dorzolamide-timolol and latanoprost","slug":"dorzolamide-timolol-and-latanoprost","indication":"Open-angle glaucoma","status":"marketed"},{"name":"Dorzolamide-timolol-brimonidine and latanoprost","genericName":"Dorzolamide-timolol-brimonidine and latanoprost","slug":"dorzolamide-timolol-brimonidine-and-latanoprost","indication":"Open-angle glaucoma","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Moxifloxacin / Dexamethasone Ophthalmic Solution","genericName":"Moxifloxacin / Dexamethasone Ophthalmic Solution","slug":"moxifloxacin-dexamethasone-ophthalmic-solution","indication":"Bacterial conjunctivitis","status":"phase_3"},{"name":"Moxifloxacin Hydrochloride, Ophthalmic","genericName":"Moxifloxacin Hydrochloride, Ophthalmic","slug":"moxifloxacin-hydrochloride-ophthalmic","indication":"Bacterial conjunctivitis","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Difluprednate 0.05%","genericName":"Difluprednate 0.05%","slug":"difluprednate-0-05","indication":"Inflammation and pain following ocular surgery","status":"phase_3"}]}],"pipeline":[{"name":"PRO-148","genericName":"PRO-148","slug":"pro-148","phase":"phase_3","mechanism":"PRO-148 is an ophthalmic anti-inflammatory agent designed to reduce ocular surface inflammation and associated symptoms.","indications":["Dry eye disease"],"catalyst":""},{"name":"Alleance®","genericName":"Alleance®","slug":"alleance","phase":"phase_3","mechanism":"Alleance® is an ophthalmic formulation designed to treat dry eye disease by lubricating and protecting the ocular surface.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"Artelac","genericName":"Artelac","slug":"artelac","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dorzolamide-timolol and latanoprost","genericName":"Dorzolamide-timolol and latanoprost","slug":"dorzolamide-timolol-and-latanoprost","phase":"marketed","mechanism":"This combination reduces intraocular pressure through three mechanisms: dorzolamide inhibits carbonic anhydrase to decrease aqueous humor production, timolol blocks beta-adrenergic receptors to reduce aqueous humor secretion, and latanoprost increases uveoscleral outflow of aqueous humor.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Dorzolamide-timolol-brimonidine and latanoprost","genericName":"Dorzolamide-timolol-brimonidine and latanoprost","slug":"dorzolamide-timolol-brimonidine-and-latanoprost","phase":"marketed","mechanism":"This fixed-dose combination reduces intraocular pressure through four complementary mechanisms: carbonic anhydrase inhibition, beta-adrenergic blockade, alpha-2 adrenergic agonism, and prostaglandin F analog activity.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Meticel Ofteno®","genericName":"Meticel Ofteno®","slug":"meticel-ofteno","phase":"marketed","mechanism":"Meticel Ofteno is a topical ophthalmic preparation containing methylcellulose that lubricates and protects the ocular surface.","indications":["Dry eye syndrome","Ocular irritation and discomfort","Lubricant for ophthalmic procedures"],"catalyst":""},{"name":"Sodium hyaluronate 0.4%","genericName":"Sodium hyaluronate 0.4%","slug":"sodium-hyaluronate-0-4","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Corneregel","genericName":"Corneregel","slug":"corneregel","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Difluprednate 0.05%","genericName":"Difluprednate 0.05%","slug":"difluprednate-0-05","phase":"phase_3","mechanism":"Difluprednate is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","indications":["Inflammation and pain following ocular surgery","Anterior uveitis","Allergic conjunctivitis","Corneal injury"],"catalyst":""},{"name":"Krytantek","genericName":"Krytantek","slug":"krytantek","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Krytantek Ofteno®","genericName":"Krytantek Ofteno®","slug":"krytantek-ofteno","phase":"phase_3","mechanism":"Krytantek Ofteno is a topical ophthalmic formulation designed to reduce intraocular pressure in glaucoma by enhancing aqueous humor outflow or reducing aqueous humor production.","indications":["Glaucoma (intraocular pressure reduction)"],"catalyst":""},{"name":"Manzanilla Sophia®","genericName":"Manzanilla Sophia®","slug":"manzanilla-sophia","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Meticel Ofteno® 0.5%","genericName":"Meticel Ofteno® 0.5%","slug":"meticel-ofteno-0-5","phase":"marketed","mechanism":"Meticel Ofteno is a topical ophthalmic solution containing methylcellulose that acts as a lubricating and protective agent for the ocular surface.","indications":["Dry eye syndrome / Keratoconjunctivitis sicca","Ocular surface protection and lubrication"],"catalyst":""},{"name":"Moxifloxacin / Dexamethasone Ophthalmic Solution","genericName":"Moxifloxacin / Dexamethasone Ophthalmic Solution","slug":"moxifloxacin-dexamethasone-ophthalmic-solution","phase":"phase_3","mechanism":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone is a corticosteroid that reduces inflammation in the eye.","indications":["Bacterial conjunctivitis","Post-operative ocular inflammation and infection","Corneal ulcers with bacterial infection"],"catalyst":""},{"name":"Moxifloxacin Hydrochloride, Ophthalmic","genericName":"Moxifloxacin Hydrochloride, Ophthalmic","slug":"moxifloxacin-hydrochloride-ophthalmic","phase":"phase_3","mechanism":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.","indications":["Bacterial conjunctivitis","Bacterial keratitis","Bacterial corneal ulcer","Post-operative ocular infections"],"catalyst":""},{"name":"Optive®","genericName":"Optive®","slug":"optive","phase":"marketed","mechanism":"Optive is an artificial tear solution that lubricates and protects the ocular surface to relieve symptoms of dry eye disease.","indications":["Dry eye disease / Keratoconjunctivitis sicca"],"catalyst":""},{"name":"PRO-087","genericName":"PRO-087","slug":"pro-087","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PRO-155","genericName":"PRO-155","slug":"pro-155","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PRO-167","genericName":"PRO-167","slug":"pro-167","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Prednefrin","genericName":"Prednefrin","slug":"prednefrin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sodium Hyaluronate Ophthalmic 0.4%","genericName":"Sodium Hyaluronate Ophthalmic 0.4%","slug":"sodium-hyaluronate-ophthalmic-0-4","phase":"marketed","mechanism":"Sodium hyaluronate acts as a lubricating and hydrating agent that coats the ocular surface to relieve dry eye symptoms.","indications":["Dry eye syndrome / Keratoconjunctivitis sicca","Ocular surface irritation and discomfort"],"catalyst":""},{"name":"Sodium hyaluronate 0.15%","genericName":"Sodium hyaluronate 0.15%","slug":"sodium-hyaluronate-0-15","phase":"marketed","mechanism":"Sodium hyaluronate is a viscoelastic substance that lubricates and protects the ocular surface by mimicking natural tear film.","indications":["Dry eye syndrome","Ocular surface protection during ophthalmic surgery","Post-operative ocular surface care"],"catalyst":""},{"name":"Systane Ultra Preservative Free","genericName":"Systane Ultra Preservative Free","slug":"systane-ultra-preservative-free","phase":"marketed","mechanism":"Systane Ultra Preservative Free is an artificial tear solution that lubricates and protects the ocular surface to relieve dry eye symptoms.","indications":["Dry eye disease / Keratoconjunctivitis sicca","Ocular surface irritation and discomfort"],"catalyst":""},{"name":"Zymar®","genericName":"Zymar®","slug":"zymar","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPOURLUFZqLWVPQmg0ZkxkdnhlcW9Vcmw4bkhqa0UwckV6WmdhQVRrSkU2ZllQREJiamYwMGZ4LWpVNmR0MGlyUVFKb1RxMmlNZTRnVjNza0h6QTdNR3p4OUoyV2tZSy1vZHhqQXJHVTQ0RGxvbVVndzZQSm9jTVhTaUxJb3dodDhOaDJlVUppZVo4TjRRZG93djR0THpNY2xFOE05T0pGUEp2NUh3Rm9yTFA3cmlObUMxamUtSjZQTlRnYlI5aHZncTFtaFZxeWRjTHV4NmpIQmxFdGQ4a0MxczNBTUNUOWtJbG5xaDZkQkxJQWlOSGlLZW9zMFc4TlloNnpLc2NOZElOeTFkQ21Zb2t1Vmh1eVY4T3VmQnExYVBQc0lGa1ZEUkFHdGI5SkkwRHFz?oc=5","date":"2026-03-17","type":"trial","source":"Mena FN","summary":"Myopia Pipeline 2026: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight Ziemer Group, NIDEK CO., LTD, 2Eyesvision, Carl Zeiss AG, Alcon, Coopervision, Topcon Healthcare - Mena FN","headline":"Myopia Pipeline 2026: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight Ziemer Group, NIDEK CO., L","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNUzN1MEE0NTlVbzNzYkRsc2ZNVXFjX002SEpKcW91U3gzNGRrRVdyakd2bjBVbWlUSjVrTkZPekxuOERHeWt4dEwxNVR4YzZkamZiY21td2N3b2RNdWNNeVNNcjV3ZmliWlJ1ZmNwMTBudmktaUI0RkJzekpxa3QwY2t0all1Si1LZ2FNN21ZcTZuNFBwZWhfSld0cjA4MEVMdktmQ1FTM3ZrM2V5cFVMbDdwVTFQY01yWjZkX04yNnlRVTVxbXlKLTd3MHNXc2habEp0TTNYcXpuaG42SkJMcmVtaHNxUmt3RVdQbTZDNGQwUjR6LWVWN0NvbEpvenlkWk5ZWXp3?oc=5","date":"2026-03-12","type":"trial","source":"StreetInsider","summary":"Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - StreetInsider","headline":"Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNeGh0c3VweFFnWmVnRkFPQ3JtTnFRWXBMbFYxdVdvR0ltWlBqV3BHZnczVFZfaVc1V0NBY3l3WDU3dW55TkZhQTVtV082RFFjRU1MYlEzcFBnN1NiNUJLa2U3empwZ3NVZklCb1ZsY0RWQ2U1WFRBSktRZXljWFFLWkQtQTNQVUNHY2puQkhVYUdUMWhTQzhYQXFJbFdJMEhIMkVsVkZ0ZldPa2cwMWdEOW1IQUN4N2lCMXg3bUJSTXRzWV9mb1FpaklQMGphUmVxNWtlRzRiUmN0UjZUd0VRalBfaDRiOE5aWnhucTVsaWdCamdSUEQ5SzBWYw?oc=5","date":"2025-05-15","type":"pipeline","source":"GlobeNewswire","summary":"Global Intraocular Lens Market to Witness Upsurge in Growth at a CAGR of ~5% by 2032 | DelveInsight - GlobeNewswire","headline":"Global Intraocular Lens Market to Witness Upsurge in Growth at a CAGR of ~5% by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQMHhfSGI1a3NjMkNsRC1ZdkRNUzJnS0FnMkhZbFBiRWF2Ykp0cHlVQ3IyZVRsZWNQQjNEaW5ESUd5V0ktU3NYYnI4NHAxT0tDLVFQZ0dDMlhyekNqZzI4RnRhX3FXV3VnX1VFODIwMkRvdUwxMEJqRlBjNnkwRktlODhwSEJOWEVVaERzXzlPTGdpSDNITmpFWXdjYldwUHkwWXVldjZXSkp6N3lZWC1LOEtqOGJRY05NdU52V1JFejhKX1BFS3NXRG1wd0NnckxyNmdIRWxoUGVnalJOeWp3Rl9TaDNHYThTOHc?oc=5","date":"2025-03-25","type":"pipeline","source":"prnewswire.com","summary":"ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight - prnewswire.com","headline":"ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxONzJwRzBpN1dGQ1h1QkRLdEFDQnRrcTJhMUkwSTJRdk9uZWJkVUZOd2VNel8tTWlJYzZkSzdJSG9nRXRuZFpkVFpEV1RKMDBvTWlkNnRaN3BzVUU5SWdZZDVwc1djWWhEaVhPRjlxWS15RDRJbm9hS29hQllqQktObGtUTDZ6OHlRQ2F4ZGlNQzFRUlpNakd2MkdiU244N3hLX3lka3FHS3VoTlVtbzJ2LXk2UHJ0ckZ5VjdGUi1MSUFRaU5YX2kxb2tOUnJoUFItM256NTFaaHhRSlpFRjdNVWE1eEZmY3RzdW5LZmZGcmI4dEVaNFlWcmZFQ3RXRVhfaGctMVhYTm9pdVMyaUx4ZC1feDh1SGk2czRLRUJzaDQydWVlWUdQUFR6bzJ5c09PaUtCWFNoQQ?oc=5","date":"2025-02-26","type":"pipeline","source":"GlobeNewswire","summary":"DURYSTA’s Market Potential Across the 7MM is Set to Soar - GlobeNewswire","headline":"DURYSTA’s Market Potential Across the 7MM is Set to Soar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQQ1FPcDBjSjVDNWtNRUJCSE05UnhfUVNYWnNWTkdobkwxdlltY3NnMWQ3SjdJWUIwRXpjODdHWUN1U3NLTEFuY19PRXJaaHpvb1pNUTFNMTd6UHBjZkpBTS14VTVfLUFuMk0tRlVFbXEyQm1lbmhRTzRBQ3hQOU5VeXB0T0NESEIzYV9uOTJqX1FSVzNQVURN?oc=5","date":"2024-06-09","type":"pipeline","source":"World Intellectual Property Organization (WIPO)","summary":"R&D-led Expansion in a Competitive Market - World Intellectual Property Organization (WIPO)","headline":"R&D-led Expansion in a Competitive Market - World Intellectual Property Organization (WIPO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQUWcweXVRV2MyUW1WQjhQY3h6SkNQbkhVenZ2MFBrWDFLX0dLT2lpRWFVVXRMVDh6X0VzelNfR0wtNE82V0RhU0tMczQwcHZKblF2RXcyeGd5N09reHJMQ0loR0hhWFNLQnJJYy1INTRVSWlxV1RZRllZZkdhZEtwbnFjRFdyQ3Jld09LRGZRT0RXMmxlR2Q3SnpjNy1oa0RqYXAyWl9UODVLSnRlcjREaEpIcmZNdVZTOXpJQ1lfM282RXNGMExJUVRB?oc=5","date":"2023-11-20","type":"pipeline","source":"Ophthalmology Advisor","summary":"Preservative-Free Sodium Hyaluronate Drop Improves Dry Eye for 50% After 1 Month - Ophthalmology Advisor","headline":"Preservative-Free Sodium Hyaluronate Drop Improves Dry Eye for 50% After 1 Month","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-10-19","type":"trial","source":"prnewswire.com","summary":"Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies - Nevakar, Vyluma, Bausch & Lomb, Sydnexis, Ocumension, ORA, LENZ Ther","headline":"Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9YNFVmSHMyM3duT1ZnRnhFa2lfdDNCcEREX0FVTHl5U3A4SzhXLTdXN2ZFSHZCbi1WZUl5YzlzdFFWYXV5dE1Dd1JFRE9DU2ZFdGgybWw0RzZNSmttZjlnMmpReVJPQzh5Nnk4?oc=5","date":"2022-03-11","type":"pipeline","source":"Wiley Online Library","summary":"Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate - Wiley Online Library","headline":"Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% o","sentiment":"neutral"}],"patents":[],"drugCount":24,"phaseCounts":{"phase_3":7,"phase_1":3,"marketed":13,"discontinued":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}